Cargando…

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients

Toll-like receptor (TLR) agonists can reactivate HIV from latently infected cells in vitro. We aimed to investigate the TLR-9 agonist, CPG 7909's in vivo effect on the proviral HIV reservoir and HIV-specific immunity. This was a post-hoc analysis of a double-blind randomized controlled vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winckelmann, Anni A., Munk-Petersen, Lærke V., Rasmussen, Thomas A., Melchjorsen, Jesper, Hjelholt, Thomas J., Montefiori, David, Østergaard, Lars, Søgaard, Ole S., Tolstrup, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637371/ https://www.ncbi.nlm.nih.gov/pubmed/23637967 http://dx.doi.org/10.1371/journal.pone.0062074

Ejemplares similares

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
por: Winckelmann, Anni, et al.
Publicado: (2017)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
por: Rasmussen, Thomas A, et al.
Publicado: (2011)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults
por: Johannesson, Thomas G., et al.
Publicado: (2012)

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
por: Krarup, Astrid Raaby, et al.
Publicado: (2017)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

HSV-1-induced chemokine expression via IFI16-dependent and IFI16-independent pathways in human monocyte-derived macrophages
por: Søby, Stine, et al.
Publicado: (2012)

Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles
por: Kirkegaard, Tea, et al.
Publicado: (2011)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

DC-based immunotherapy as strategy to purge the HIV reservoir?
por: Søgaard, Ole S.
Publicado: (2019)

Proviral Quasispecies Diversity Is Not Associated With Virologic Breakthrough or CD4(+) T Cell Loss in HIV-1 Elite Controllers
por: de Azevedo, Suwellen S. D., et al.
Publicado: (2019)

A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir
por: Levy, Claire N., et al.
Publicado: (2021)

Learning from the Messengers: Innate Sensing of Viruses and Cytokine Regulation of Immunity—Clues for Treatments and Vaccines
por: Melchjorsen, Jesper
Publicado: (2013)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART
por: Brooks, Kelsie, et al.
Publicado: (2021)

Intact Proviral DNA Analysis of the Brain Viral Reservoir and Relationship to Neuroinflammation in People with HIV on Suppressive Antiretroviral Therapy
por: Gabuzda, Dana, et al.
Publicado: (2023)

Ongoing HIV-1 evolution and reservoir reseeding in two elite controllers with genetically diverse peripheral proviral quasispecies
por: de Azevedo, Suwellen Sardinha Dias, et al.
Publicado: (2023)

Immunomodulation with IL-7 and IL-15 in HIV-1 infection
por: Gunst, Jesper D., et al.
Publicado: (2023)

Epigenetic drug Gar1041 in combination with antiretroviral therapy transiently reduces the proviral DNA reservoir in SIVmac251-infected macaques
por: Lewis, MG, et al.
Publicado: (2010)

Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption
por: Wang, Xiaolei, et al.
Publicado: (2021)

Dating reservoir formation in virologically suppressed people living with HIV-1 in Rakai, Uganda
por: Kankaka, Edward Nelson, et al.
Publicado: (2023)

Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis
por: Ostrowski, Sisse R., et al.
Publicado: (2021)

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets
por: Konrad, Christina V., et al.
Publicado: (2023)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Sustained Virologic Suppression Reduces HIV-1 DNA Proviral Levels and HIV Antibodies in Perinatally HIV-Infected Children Followed from Birth
por: Fuller, Trevon, et al.
Publicado: (2022)

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)

Development of sensitive ddPCR assays to reliably quantify the proviral DNA reservoir in all common circulating HIV subtypes and recombinant forms
por: Bosman, Kobus J, et al.
Publicado: (2018)

Protocol for high-throughput reservoir quantification across global HIV subtypes using a cross-subtype intact proviral DNA assay
por: Fish, Carolyn S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_48lfu4q86kcr1fjkidnjb0651m